Rafael Holdings, Inc. (NYSE:RFL – Get Free Report) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 33,970 shares, a decline of 15.1% from the March 15th total of 40,019 shares. Based on an average trading volume of 59,841 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.1% of the company’s shares are sold short.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Rafael in a research report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on Rafael
Institutional Inflows and Outflows
Rafael Stock Up 4.1%
NYSE:RFL traded up $0.05 during mid-day trading on Friday, hitting $1.27. 63,247 shares of the stock traded hands, compared to its average volume of 49,351. The stock has a market capitalization of $66.05 million, a price-to-earnings ratio of -1.61 and a beta of 0.51. Rafael has a 52 week low of $1.12 and a 52 week high of $3.19. The firm’s 50 day moving average is $1.29 and its two-hundred day moving average is $1.28.
Rafael (NYSE:RFL – Get Free Report) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.13) EPS for the quarter. The firm had revenue of $0.21 million for the quarter. Rafael had a negative net margin of 2,846.60% and a negative return on equity of 37.27%.
About Rafael
Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.
See Also
Receive News & Ratings for Rafael Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rafael and related companies with MarketBeat.com's FREE daily email newsletter.
